Axsome Therapeutics, Inc.
AXSM
$210.63
$2.811.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 776.57M | 708.24M | 638.50M | 561.26M | 495.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 776.57M | 708.24M | 638.50M | 561.26M | 495.03M |
| Cost of Revenue | 52.53M | 52.41M | 47.48M | 45.66M | 42.19M |
| Gross Profit | 724.04M | 655.82M | 591.02M | 515.60M | 452.85M |
| SG&A Expenses | 712.67M | 634.81M | 570.60M | 514.57M | 459.90M |
| Depreciation & Amortization | 6.38M | 6.38M | 6.38M | 6.38M | 6.37M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 959.43M | 884.77M | 807.73M | 756.11M | 703.18M |
| Operating Income | -182.86M | -176.53M | -169.24M | -194.84M | -208.15M |
| Income Before Tax | -191.09M | -188.83M | -183.70M | -230.40M | -247.78M |
| Income Tax Expenses | 558.00K | -530.00K | -530.00K | -875.00K | -875.00K |
| Earnings from Continuing Operations | -191.64 | -188.30 | -183.17 | -229.53 | -246.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -191.64M | -188.30M | -183.17M | -229.53M | -246.90M |
| EBIT | -182.86M | -176.53M | -169.24M | -194.84M | -208.15M |
| EBITDA | -172.92M | -167.23M | -160.17M | -185.98M | -199.64M |
| EPS Basic | -3.76 | -3.74 | -3.69 | -4.67 | -5.07 |
| Normalized Basic EPS | -2.30 | -2.26 | -2.21 | -2.58 | -2.78 |
| EPS Diluted | -3.76 | -3.74 | -3.69 | -4.67 | -5.07 |
| Normalized Diluted EPS | -2.30 | -2.26 | -2.21 | -2.58 | -2.78 |
| Average Basic Shares Outstanding | 203.65M | 201.29M | 198.97M | 196.88M | 195.00M |
| Average Diluted Shares Outstanding | 203.65M | 201.29M | 198.97M | 196.88M | 195.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |